Drugs / BPI viper antivenom
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04210141 | Apr 2025 → Feb 2027 | snakebite envenomation | Myanmar Oxford Clinical Research Unit | Suspended | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BPI viper antivenom | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04210141 ↗ |
| Known as | Viper antivenom BPI | “production of a new monospecific lyophilized F(ab)'2 antivenom (Viper antivenom BPI)” NCT04210141 ↗ |
| Modality | Protein / enzyme biologic | “new monospecific lyophilized F(ab)'2 antivenom” NCT04210141 ↗ |